Timothy Geoffrey Barrett

Timothy Geoffrey Barrett

Auto-generated profile, based on publicly available information

Timothy Geoffrey Barrett

Institute of Child Health, University of Birmingham, Birmingham, UK

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2000 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MDMarc Delépine
Marc Delépine
MNMarc Nicolino
Marc Nicolino
TBTimothy Barrett
Timothy Barrett
MGMahamadee Golamaully
Mahamadee Golamaully
GLG. Mark Lathrop
G. Mark Lathrop
CJCécile Julier
Cécile Julier

1 October 2004 in The Lancet
Verified
Journal Article
Closed access
EFEdith Ch Friesema
Edith Ch Friesema
AGAnnette Grueters
Annette Grueters
HBHeike Biebermann
Heike Biebermann
HKHeiko Krude
Heiko Krude
AMArpad von Moers
Arpad von Moers
TVTheo J Visser
Theo J Visser

1 December 1995 in The Lancet
Verified
Journal Article
Closed access
TBT.G Barrett
T.G Barrett
SBS.E Bundey
S.E Bundey
AMA.F Macleod
A.F Macleod

3 April 2007 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
EPEwan R Pearson
Ewan R Pearson
SBSylvia F Boj
Sylvia F Boj
ASAnna M Steele
Anna M Steele
TBTimothy Barrett
Timothy Barrett
KSKaren Stals
Karen Stals
AHAndrew T Hattersley
Andrew T Hattersley
Macrosomia is associated with considerable neonatal and maternal morbidity. Factors that predict macrosomia are poorly understood. The increased rate of macrosomia in the offspring of pregnant women with diabetes and in congenital hyperinsulinaemia is mediated by increased foetal insulin secretion. We assessed the in utero and neonatal role of two key regulators of pancreatic insulin secretion by studying birthweight and the incidence of neonatal hypoglycaemia in patients with heterozygous mutations in the maturity-onset diabetes of the young (MODY) genes HNF4A (encoding HNF-4α) and HNF1A/TCF1 (encoding HNF-1α), and the effect of pancreatic deletion of Hnf4a on foetal and neonatal insulin secretion in mice. We examined birthweight and hypoglycaemia in 108 patients from families with diabetes due to HNF4A mutations, and 134 patients from families with HNF1A mutations. Birthweight was increased by a median of 790 g in HNF4A-mutation carriers compared to non-mutation family members (p < 0.001); 56% (30/54) of HNF4A-mutation carriers were macrosomic compared with 13% (7/54) of non-mutation family members (p < 0.001). Transient hypoglycaemia was reported in 8/54 infants with heterozygous HNF4A mutations, but was reported in none of 54 non-mutation carriers (p = 0.003). There was documented hyperinsulinaemia in three cases. Birthweight and prevalence of neonatal hypoglycaemia were not increased in HNF1A-mutation carriers. Mice with pancreatic β-cell deletion of Hnf4a had hyperinsulinaemia in utero and hyperinsulinaemic hypoglycaemia at birth. HNF4A mutations are associated with a considerable increase in birthweight and macrosomia, and are a novel cause of neonatal hypoglycaemia. This study establishes a key role for HNF4A in determining foetal birthweight, and uncovers an unanticipated feature of the natural history of HNF4A-deficient diabetes, with hyperinsulinaemia at birth evolving to decreased insulin secretion and diabetes later in life.

15 August 2019 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
WTWilliam V. Tamborlane
William V. Tamborlane
MBMargarita Barrientos-Pérez
Margarita Barrientos-Pérez
UFUdi Fainberg
Udi Fainberg
HFHelle Frimer-Larsen
Helle Frimer-Larsen
MHMona Hafez
Mona Hafez
TBTimothy Barrett
Timothy Barrett
Metformin is the regulatory-approved treatment of choice for most youth with type 2 diabetes early in the disease. However, early loss of glycemic control has been observed with metformin monotherapy. Whether liraglutide added to metformin (with or without basal insulin treatment) is safe and effective in youth with type 2 diabetes is unknown. Patients who were 10 to less than 17 years of age were randomly assigned, in a 1:1 ratio, to receive subcutaneous liraglutide (up to 1.8 mg per day) or placebo for a 26-week double-blind period, followed by a 26-week open-label extension period. Inclusion criteria were a body-mass index greater than the 85th percentile and a glycated hemoglobin level between 7.0 and 11.0% if the patients were being treated with diet and exercise alone or between 6.5 and 11.0% if they were being treated with metformin (with or without insulin). All the patients received metformin during the trial. The primary end point was the change from baseline in the glycated hemoglobin level after 26 weeks. Secondary end points included the change in fasting plasma glucose level. Safety was assessed throughout the course of the trial. Of 135 patients who underwent randomization, 134 received at least one dose of liraglutide (66 patients) or placebo (68 patients). Demographic characteristics were similar in the two groups (mean age, 14.6 years). At the 26-week analysis of the primary efficacy end point, the mean glycated hemoglobin level had decreased by 0.64 percentage points with liraglutide and increased by 0.42 percentage points with placebo, for an estimated treatment difference of −1.06 percentage points (P<0.001); the difference increased to −1.30 percentage points by 52 weeks. The fasting plasma glucose level had decreased at both time points in the liraglutide group but had increased in the placebo group. The number of patients who reported adverse events was similar in the two groups (56 [84.8%] with liraglutide and 55 [80.9%] with placebo), but the overall rates of adverse events and gastrointestinal adverse events were higher with liraglutide. In children and adolescents with type 2 diabetes, liraglutide, at a dose of up to 1.8 mg per day (added to metformin, with or without basal insulin), was efficacious in improving glycemic control over 52 weeks. This efficacy came at the cost of an increased frequency of gastrointestinal adverse events. (Funded by Novo Nordisk; Ellipse ClinicalTrials.gov number, NCT01541215.)

1 July 1999 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
VLValentina Labay
Valentina Labay
TRTal Raz
Tal Raz
DBDana Baron
Dana Baron
HMHanna Mandel
Hanna Mandel
HWHawys Williams
Hawys Williams
NCNadine Cohen
Nadine Cohen